A Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain
2상
조기 종료
NCT05895552
| 대상 질환 | Diabetic Peripheral Neuropathic Pain |
|---|
| 임상 단계 | 2상 |
|---|
| 스폰서 | Reata, a wholly owned subsidiary of Biogen |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 209 명 |
|---|
| 중재(약물) | RTA 901, RTA 901-Matching Placebo |
|---|
| 시작일 | 2023년 7월 28일 |
|---|
| 완료일 | 2024년 11월 15일 |
|---|
| 결과 공개일 | 2025년 12월 15일 |
|---|
요약
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of RTA 901 in qualified participants with Diabetic Peripheral Neuropathic Pain (DPNP). Each study part will be randomized into 3 treatment arms; 2 different doses of RTA 901 and RTA 901-maching placebo. The doses of RTA 901 in Part 2 will be selected based on the Exposure-Response (E-R) analyses of data from Part 1. The duration of each part of the study will be approximately 20 weeks, including a Screening period of up to 2 weeks, a Run-in-period of 2 weeks, a Treatment period of 12 weeks, and a Follow-up period of 4 weeks. All participants in Part 1 and Part 2 of the study will follow the same visit and assessment schedule. Eligibility will be assessed during the Screening and Run-in-periods.
Change From Baseline in Weekly Average Pain Intensity Assessed by the Numeric Pain Rating Scale (NPRS) at Week 12
Baseline, Week 12 · score on a scale
| Part 1: RTA 901 Matching Placebo + SOC | -1.71 ± 0.249 score on a scale |
|---|
| Part 1: RTA 901 10 mg + SOC | -1.49 ± 0.248 score on a scale |
|---|
| Part 1: RTA 901 80 mg + SOC | -1.79 ± 0.248 score on a scale |
|---|
| p-value | <0.5224 |
|---|
| Least square (LS) mean difference | 0.23 (95% CI -0.468–0.918) |
|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) During and Following the Treatment Period
From the first dose of study drug up to end of follow-up period (up to 16 weeks) · Participants
| Part 1: RTA 901 Matching Placebo + SOC | 39 Participants |
|---|
| Part 1: RTA 901 10 mg + SOC | 43 Participants |
|---|
| Part 1: RTA 901 80 mg + SOC | 35 Participants |
|---|
| Part 1: RTA 901 Matching Placebo + SOC | 4 Participants |
|---|
| Part 1: RTA 901 10 mg + SOC | 5 Participants |
|---|
| Part 1: RTA 901 80 mg + SOC | 1 Participants |
|---|
Number of Participants With Clinically Significant Abnormalities in Physical Examinations
From the first dose of study drug up to end of follow-up period (up to 16 weeks) · Participants
| Part 1: RTA 901 Matching Placebo + SOC | 0 Participants |
|---|
| Part 1: RTA 901 10 mg + SOC | 0 Participants |
|---|
| Part 1: RTA 901 80 mg + SOC | 0 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.